On August 8, Associate Professor Satoshi Takagi of the Animal Medical Center of Hokkaido University, Associate Professor Satoshi Imauchi of the Graduate School of Veterinary Medicine, and Visiting Professor Yumiko Kagawa et al. Announced the development of a canine chimeric anti-PD-L25 antibody.
About 3% of dogs die from cancer, and the older they get, the higher the chance of getting cancer.Surgery, radiotherapy, and chemotherapy are used as the three major therapies as treatment methods, but these have a high burden on the dog's body and there are many restrictions on their use, so the development of new treatment methods is desired. Was there.
The research group has previously reported the frequent expression of PD-L1 in intractable canine tumors.This time, we have developed a rat-dog chimeric anti-PD-L1 antibody as an immune checkpoint inhibitor that can be applied to the treatment of canine tumors.
As a result of clinical applied research, a clear tumor regression effect was confirmed in some dogs with malignant melanoma and undifferentiated sarcoma.It was also suggested that malignant melanoma has the effect of prolonging survival after metastasis to the lung.It is said that this development technology is a promising result as a therapeutic drug for intractable canine tumors such as malignant melanoma.
Paper information:[Scientific Reports] A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma
